Peng Huang1,2, Yan Wang1, Ming Yue3, Zhijun Ge4, Xueshan Xia5, Andre J Jeyarajan2, Jacinta A Holmes6, Rongbin Yu1, Chuanwu Zhu7, Sheng Yang8, Wenyu Lin2, Raymond T Chung2. 1. Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. 2. Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 4. Department of Critical Care Medicine, The Affiliated Yixing Hospital of Jiangsu University, Yixing, China. 5. Faculty of Life Science and Technology, Kunming University of Science and Technology of Science and Technology, Kunming, China. 6. Department of Gastroenterology, St. Vincent's Hospital, Fitzroy, Victoria, Australia. 7. Department of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, China. 8. Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Abstract
BACKGROUND & AIMS: The risk for hepatitis C virus (HCV) recurrence persists after HCV eradication with direct-acting antivirals (DAAs), particularly in patients with ongoing high-risk behaviours. Our aim was to assess the risk of HCV recurrence (late relapse and/or reinfection) post-sustained virological response (SVR). METHODS: We searched the literature for studies reporting HCV recurrence rates post-SVR in PubMed, Web of Science and the Cochrane Library. Identified publications were divided into groups based on patient risk for HCV reinfection: low-risk HCV mono-infection, high-risk HCV mono-infection and a human immunodeficiency virus (HIV)/HCV coinfection. The HCV recurrence rate for each study was calculated by using events divided by the person-years of follow-up (PYFU). HCV recurrence was defined as confirmed, detectable HCV RNA post-SVR. RESULTS: In the 16 studies of low-risk patients, the pooled recurrence rate was 0.89/1000 PYFU (95% confidence interval [CI], 0.16-2.03). For the 19 studies of high-risk patients, the pooled recurrence rate was 29.37/1000 PYFU (95% CI, 15.54-46.91). For the eight studies of HIV/HCV-coinfected patients, the pooled recurrence rate was 23.25/1000 PYFU (95% CI, 4.24-53.39). The higher pooled estimates of recurrence in the high-risk and HIV/HCV-coinfected populations were predominantly driven by an increase in reinfection rather than late relapse. CONCLUSIONS: The HCV recurrence risk after achieving SVR with all-oral DAAs therapy is low, and the risk of HCV recurrence in high-risk and HIV/HCV-coinfected populations was driven by an increase in reinfection rather than late relapse.
BACKGROUND & AIMS: The risk for hepatitis C virus (HCV) recurrence persists after HCV eradication with direct-acting antivirals (DAAs), particularly in patients with ongoing high-risk behaviours. Our aim was to assess the risk of HCV recurrence (late relapse and/or reinfection) post-sustained virological response (SVR). METHODS: We searched the literature for studies reporting HCV recurrence rates post-SVR in PubMed, Web of Science and the Cochrane Library. Identified publications were divided into groups based on patient risk for HCV reinfection: low-risk HCV mono-infection, high-risk HCV mono-infection and a human immunodeficiency virus (HIV)/HCV coinfection. The HCV recurrence rate for each study was calculated by using events divided by the person-years of follow-up (PYFU). HCV recurrence was defined as confirmed, detectable HCV RNA post-SVR. RESULTS: In the 16 studies of low-risk patients, the pooled recurrence rate was 0.89/1000 PYFU (95% confidence interval [CI], 0.16-2.03). For the 19 studies of high-risk patients, the pooled recurrence rate was 29.37/1000 PYFU (95% CI, 15.54-46.91). For the eight studies of HIV/HCV-coinfected patients, the pooled recurrence rate was 23.25/1000 PYFU (95% CI, 4.24-53.39). The higher pooled estimates of recurrence in the high-risk and HIV/HCV-coinfected populations were predominantly driven by an increase in reinfection rather than late relapse. CONCLUSIONS: The HCV recurrence risk after achieving SVR with all-oral DAAs therapy is low, and the risk of HCV recurrence in high-risk and HIV/HCV-coinfected populations was driven by an increase in reinfection rather than late relapse.
Authors: Evan B Cunningham; Behzad Hajarizadeh; Janaki Amin; Margaret Hellard; Julie Bruneau; Jordan J Feld; Curtis Cooper; Jeff Powis; Alain H Litwin; Philippa Marks; Olav Dalgard; Brian Conway; Alberto Moriggia; Catherine Stedman; Phillip Read; Philip Bruggmann; Karine Lacombe; Adrian Dunlop; Tanya L Applegate; Gail V Matthews; Chris Fraser; Gregory J Dore; Jason Grebely Journal: Clin Infect Dis Date: 2021-04-26 Impact factor: 9.079
Authors: Edward J Gane; Christian Schwabe; Robert H Hyland; Yin Yang; Evguenia Svarovskaia; Luisa M Stamm; Diana M Brainard; John G McHutchison; Catherine A Stedman Journal: Gastroenterology Date: 2016-05-27 Impact factor: 22.682
Authors: Ned H Latham; Joseph S Doyle; Anna Y Palmer; Joost W Vanhommerig; Paul Agius; Stelliana Goutzamanis; Zinia Li; Alisa Pedrana; Magnus Gottfredsson; Julie Bouscaillou; Niklas Luhmann; Alyona Mazhnaya; Frederick L Altice; Sahar Saeed; Marina Klein; Oluwaseun O Falade-Nwulia; Esther Aspinall; Sharon Hutchinson; Margaret E Hellard; Rachel Sacks-Davis Journal: Liver Int Date: 2019-06-10 Impact factor: 5.828
Authors: Esther J Aspinall; Stephen Corson; Joseph S Doyle; Jason Grebely; Sharon J Hutchinson; Gregory J Dore; David J Goldberg; Margaret E Hellard Journal: Clin Infect Dis Date: 2013-08 Impact factor: 9.079
Authors: K Rutter; H Hofer; S Beinhardt; M Dulic; M Gschwantler; A Maieron; H Laferl; A F Stättermayer; T-M Scherzer; R Strassl; H Holzmann; P Steindl-Munda; P Ferenci Journal: Aliment Pharmacol Ther Date: 2013-05-26 Impact factor: 8.171
Authors: Filomena Morisco; Rocco Granata; Tommaso Stroffolini; Maria Guarino; Laura Donnarumma; Laura Gaeta; Ilaria Loperto; Ivan Gentile; Francesco Auriemma; Nicola Caporaso Journal: World J Gastroenterol Date: 2013-05-14 Impact factor: 5.742
Authors: Alice K Asher; Carmen J Portillo; Bruce A Cooper; Carol Dawson-Rose; David Vlahov; Kimberly A Page Journal: Subst Use Misuse Date: 2016-05-24 Impact factor: 2.164
Authors: Fabien Zoulim; Christophe Moreno; Samuel S Lee; Peter Buggisch; Andrzej Horban; Eric Lawitz; Chris Corbett; Oliver Lenz; Bart Fevery; Thierry Verbinnen; Umesh Shukla; Wolfgang Jessner Journal: Virol J Date: 2018-01-30 Impact factor: 4.099